EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial

Xingqi Zhang, Yanting Ye, Weiling Sun, Youyu Sheng, Misaki Kinoshita-Ise iD, Taisuke Ito iD, Cheng-Che Lan iD, Ohsang Kwon iD, Gregor Schaefer, Robert Wolk, Shasha Hu, Qiankun Sun und 2 weitere

The Journal of Dermatology · 2025-04 · 52 (4) · 603-614

DOI: 10.1111/1346-8138.17539 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Dermatology, online erschienen am 12.03.2025. Verfasst von Xingqi Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Alopecia Areata, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This subgroup analysis of the ALLEGRO phase 2b/3 study (NCT3732807) assessed the efficacy and safety of multiple doses of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in Asian patients with alopecia areata (AA). Patients aged ≥12 years with AA and ≥50% scalp hair loss received once‐daily ritlecitinib 50 or 30 mg (with or without 4‐week 200‐mg loading dose [“200/50” or “200/30”]) or 10 mg or placebo for 24 weeks, followed by a 24‐week extension, in which patients initially assigned to placebo switched to 200/50 or 50 mg. In this subgroup analysis, Asian patients with response based on achieving a Severity of Alopecia Tool (SALT) score ≤20, SALT ≤10, ≥2‐grade improvement or normal score on the eyebrow assessment (EBA) scale, and ≥2‐grade improvement or normal score on the eyelash assessment (ELA) scale were evaluated through week 48. Safety was monitored throughout. In total, 186 Asian patients were randomized to ritlecitinib 200/50 mg ( n = 33), 200/30 mg ( n = 28), 50 mg ( n = 43), 30 mg ( n = 34), 10 mg ( n = 17), placebo to 200/50 mg ( n = 14), or placebo to 50 mg ( n = 17). The proportions of patients treated with ritlecitinib ≥30 mg achieving a SALT score ≤20 response were 9.1%–36.4% at week 24 vs 0% for the 10‐mg group and 3.2% for placebo. At week 48, 26.5%–55.6% of patients treated with ritlecitinib ≥30 mg achieved a SALT ≤20 response. At week 48, the proportions of patients treated with ritlecitinib ≥30 mg with EBA response were 41.9%–71.1% and with ELA response were 40.7%–57.9%. The most common adverse events were nasopharyngitis, folliculitis, upper respiratory tract infection, and urticaria. No serious or opportunistic infections, major adverse cardiovascular events, thromboembolic events, malignancies, or deaths were reported. Ritlecitinib demonstrated clinical efficacy and acceptable safety over 48 weeks in Asian patients ≥12 years with AA and ≥50% hair loss. Results for the Asian subpopulation were consistent with the overall population in the ALLEGRO‐2b/3 study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataProtein Kinase InhibitorsHumansMaleAdultFemaleMiddle AgedAsian PeopleTreatment OutcomeYoung AdultAdolescentDouble-Blind MethodSeverity of Illness IndexDose-Response Relationship, DrugDrug Administration ScheduleAged

Stichwörter der Autor:innen

ALLEGROSALTSeverity of Alopecia Toolalopecia areataritlecitinib

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Huashan Hospital, Fudan University, Shanghai, China.
  • Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Dermatology, College of Medicine and Chung-Ho Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

ORCID-Profile: Misaki Kinoshita-Ise, Taisuke Ito, Cheng-Che Lan, Ohsang Kwon, Masayo Sakaki-Yumoto

Förderung

  • Pfizer

Zitieren

APA

Zhang, X., Ye, Y., Sun, W., Sheng, Y., Kinoshita-Ise, M., Ito, T., Lan, C. C., Kwon, O., Schaefer, G., Wolk, R., Hu, S., Sun, Q., Shen, Y., & Sakaki-Yumoto, M. (2025). Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial. The Journal of Dermatology, 52(4), 603-614. https://doi.org/10.1111/1346-8138.17539

Vancouver

Zhang X, Ye Y, Sun W, Sheng Y, Kinoshita-Ise M, Ito T, et al. Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial. The Journal of Dermatology. 2025;52(4):603-614. doi:10.1111/1346-8138.17539

BibTeX
@article{Zhang2025,
  author = {Zhang, Xingqi and Ye, Yanting and Sun, Weiling and Sheng, Youyu and Kinoshita-Ise, Misaki and Ito, Taisuke and Lan, Cheng-Che and Kwon, Ohsang and Schaefer, Gregor and Wolk, Robert and Hu, Shasha and Sun, Qiankun and Shen, Yimeng and Sakaki-Yumoto, Masayo},
  title = {Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial},
  journal = {The Journal of Dermatology},
  year = {2025},
  volume = {52},
  number = {4},
  pages = {603--614},
  doi = {10.1111/1346-8138.17539}
}
Kostenlos starten →